Publication
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Authors not recorded
N Engl J Med2023PMID 37870976stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugAmivantamabcivic_curation1.00
- drugChemotherapycivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR Exon 20 Insertioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37870976
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR Exon 20 Insertion1 | ||||||||
| Amivantamab + ChemotherapyCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12014In this phase 3 trial, 308 patients with NSCLC harbouring EGFR exon 20 insertions were treated with a combination of amivantamab and chemotherapy (carboplatin-pemetrexed) [n = 153] or chemotherapy alo… (full text at CIViC) PMID 37870976 · Zhou et al., 2023 · Open in CIViC | civic |